A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)

Inclusion Criteria:

• Signed the Informed Consent Form;
• Age ≥ 50 years of either gender;
• Total lesion size ≤ 30 mm2 of the study eye;
• BCVA score of the study eye between 73 and 19 letters;
• Clear ocular media and adequate pupil dilation to permit good quality fundus photographic imaging.
• BCVA score of the fellow eye ≥ 19 letters.

Exclusion Criteria:

• Current or previous non-exudative AMD diseases which affect the inspection and measurement of macular or the central visual acuity;
• Subretinal hemorrhage area≥ 50% of total lesion size;
• Scar or fibrosis area in study eyes ≥ 50% of total lesion size; or central foveal scar、fibrosis or atrophy of macular in the study eye;
• Presence of retinal pigment epithelial tear, retinal macular tractional, macular epiretinal membrane, and diagnosed with polypoidal choroidal vasculopathy in the study eye;
• Previous anti-VEGF drug treatment in the study eye within six months preceding screening; or anti-VEGF treatment in the fellow eye within three months before screening;
• Previous intraocular or periocular operations, excluding operations on eyelid without hampering the intravitreal injection in the study eye;
• Previous ophthalmologic operations in the study eye;
• Current active inflammation or infection in either eye;
• Uncontrolled previous or current glaucoma in either eye, or previous glaucoma filtering operation in the study eye;
• Current systemic administrations which may lead to toxicity in the crystalline lens;
• History of allergy or current allergic response;
• History of surgery within one month preceding enrollment;
• Infectious diseases need systemic administration;
• Systemic autoimmune diseases;
• Any uncontrolled clinical disorders;
• Patients of child-bearing potential do not adopted adequate contraception methods;
• Pregnant or nursing women;
• Patients should be excluded in the opinion of investigators;